Penn and Parker Institute Renew Multimillion-Dollar Cancer Research Collaboration

The University of Pennsylvania and the Parker Institute for Cancer Immunotherapy (PICI) have renewed their collaboration to advance cancer immunotherapy research at Penn Medicine’s Abramson Cancer Center. “Being part of PICI has opened new doors for teamwork across institutions that has already proved to be very fruitful in moving immunotherapy forward as a pillar of cancer treatment,” said Carl June, MD, the Richard W. Vague Professor in Immunotherapy and director of the Parker Institute for Cancer Immunotherapy Center at Penn. E. John Wherry, PhD, the Richard and Barbara Schiffrin President’s Distinguished Professor and chair of Systems Pharmacology and Translational Therapeutics, and Saar Gill, MD, PhD, an associate professor of Hematology-Oncology, serve as co-directors of the PICI Center at Penn.